Literature DB >> 25861945

Evidence of injection drug use in Kisumu, Kenya: Implications for HIV prevention.

Jennifer L Syvertsen1, Kawango Agot2, Spala Ohaga2, Steffanie A Strathdee3, Carol S Camlin4, Eunice Omanga2, Petronilla Odonde2, Grace Rota5, Kelvin Akoth5, Juan Peng6, Karla D Wagner7.   

Abstract

BACKGROUND: Injection drug use is increasingly contributing to the HIV epidemic across sub-Saharan Africa. This paper provides the first descriptive analysis of injection drug use in western Kenya, where HIV prevalence is already highest in the nation at 15.1%.
METHODS: We draw on quantitative data from a study of injection drug use in Kisumu, Kenya. We generated descriptive statistics on socio-demographics, sexual characteristics, and drug-related behaviors. Logistic regression models were adjusted for sex to identify correlates of self-reported HIV positive status.
RESULTS: Of 151 participants, mean age was 28.8 years, 84% (n = 127) were male, and overall self-reported HIV prevalence reached 19.4%. Women had greater than four times the odds of being HIV positive relative to men (Odds Ratio [OR] 4.5, CI: 1.7, 11.8, p = .003). Controlling for sex, ever experiencing STI symptoms (Adjusted Odds ratio [AOR] 4.6, 95% CI 1.7, 12.0, p = .002) and sharing needles or syringes due to lack of access (AOR 3.6, 95% CI 1.2, 10.5, p = .02) were significantly associated with HIV positive status. Lower education (AOR 2.3, 95% CI 0.9, 5.6, p=.08), trading sex for drugs (AOR 2.8, 95% CI 0.9, 8.8, p = .08), being injected by a peddler (AOR 2.9, 95% CI 1.0, 8.5, p = .05), and injecting heroin (AOR 2.3, 95% CI 1.0, 5.7, p = .06), were marginally associated with HIV.
CONCLUSIONS: This exploratory study identified patterns of unsafe drug injection and concurrent sexual risk in western Kenya, yet few resources are currently available to address addiction or injection-related harm. Expanded research, surveillance, and gender sensitive programming are needed.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gender; HIV interventions; Harm reduction; Heroin; Sexual risk; sub-Saharan Africa

Mesh:

Year:  2015        PMID: 25861945      PMCID: PMC4447587          DOI: 10.1016/j.drugalcdep.2015.02.037

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  13 in total

1.  Flashblood: blood sharing among female injecting drug users in Tanzania.

Authors:  Sheryl A McCurdy; Michael W Ross; Mark L Williams; Gad P Kilonzo; Melkizedek T Leshabari
Journal:  Addiction       Date:  2010-03-12       Impact factor: 6.526

Review 2.  Drug use as a driver of HIV risks: re-emerging and emerging issues.

Authors:  Nabila El-Bassel; Stacey A Shaw; Anindita Dasgupta; Steffanie A Strathdee
Journal:  Curr Opin HIV AIDS       Date:  2014-03       Impact factor: 4.283

Review 3.  Are major reductions in new HIV infections possible with people who inject drugs? The case for low dead-space syringes in highly affected countries.

Authors:  William A Zule; Harry E Cross; John Stover; Carel Pretorius
Journal:  Int J Drug Policy       Date:  2012-08-10

4.  A rapid assessment of heroin use in Mombasa, Kenya.

Authors:  Susan Beckerleg; Maggie Telfer; Ahmed Sadiq
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

5.  Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study.

Authors:  Paul Brodish; Kavita Singh; Agnes Rinyuri; Carol Njeru; Nzioki Kingola; Patrick Mureithi; William Sambisa; Sharon Weir
Journal:  Drug Alcohol Depend       Date:  2011-06-22       Impact factor: 4.492

6.  HIV and risk environment for injecting drug users: the past, present, and future.

Authors:  Steffanie A Strathdee; Timothy B Hallett; Natalia Bobrova; Tim Rhodes; Robert Booth; Reychad Abdool; Catherine A Hankins
Journal:  Lancet       Date:  2010-07-24       Impact factor: 79.321

Review 7.  Combination HIV prevention: significance, challenges, and opportunities.

Authors:  Ann E Kurth; Connie Celum; Jared M Baeten; Sten H Vermund; Judith N Wasserheit
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

8.  Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy.

Authors:  S Kelly Avants; Arthur Margolin; Mary Helen Usubiaga; Cheryl Doebrick
Journal:  J Subst Abuse Treat       Date:  2004-03

9.  Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania.

Authors:  Barrot H Lambdin; R Douglas Bruce; Olivia Chang; Cassian Nyandindi; Norman Sabuni; Sophia Zamudio-Haas; Sheryl McCurdy; Frank Masao; Yovin Ivo; Amani Msami; Omar Ubuguy; Jessie Mbwambo
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  The rise of injecting drug use in East Africa: a case study from Kenya.

Authors:  Susan Beckerleg; Maggie Telfer; Gillian Lewando Hundt
Journal:  Harm Reduct J       Date:  2005-08-25
View more
  14 in total

Review 1.  Prevalence of Kaposi's sarcoma-associated herpesvirus among intravenous drug users: a systematic review and meta-analysis.

Authors:  Qiwen Fang; Zhenqiu Liu; Zhijie Zhang; Yan Zeng; Tiejun Zhang
Journal:  Virol Sin       Date:  2017-10-13       Impact factor: 4.327

2.  You can't do this job when you are sober: Heroin use among female sex workers and the need for comprehensive drug treatment programming in Kenya.

Authors:  Jennifer L Syvertsen; Kawango Agot; Spala Ohaga; Angela Robertson Bazzi
Journal:  Drug Alcohol Depend       Date:  2018-11-13       Impact factor: 4.492

3.  A Qualitative Study of Substance use during Pregnancy: Implications for Reproductive Healthcare in Western Kenya.

Authors:  Kelly A Yotebieng; Kawango Agot; Grace Rota; Craig R Cohen; Jennifer L Syvertsen
Journal:  Afr J Reprod Health       Date:  2016-12

4.  A systematic review of substance use and substance use disorder research in Kenya.

Authors:  Florence Jaguga; Sarah Kanana Kiburi; Eunice Temet; Julius Barasa; Serah Karanja; Lizz Kinyua; Edith Kamaru Kwobah
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

5.  The Opioid Epidemic in Africa And Its Impact.

Authors:  Ann E Kurth; Peter Cherutich; Rosabelle Conover; Nok Chhun; R Douglas Bruce; Barrot H Lambdin
Journal:  Curr Addict Rep       Date:  2018-10-30

6.  Co-Infection Burden of Hepatitis C Virus and Human Immunodeficiency Virus among Injecting Heroin Users at the Kenyan Coast.

Authors:  Ruth S Mwatelah; Raphael M Lwembe; Saida Osman; Bernhards R Ogutu; Rashid Aman; Rose C Kitawi; Laura N Wangai; Florence A Oloo; Gilbert O Kokwaro; Washingtone Ochieng
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  Strategic information is everyone's business: perspectives from an international stakeholder meeting to enhance strategic information data along the HIV Cascade for people who inject drugs.

Authors:  Richard D Pierce; Jennifer Hegle; Keith Sabin; Edo Agustian; Lisa G Johnston; Stephen Mills; Catherine S Todd
Journal:  Harm Reduct J       Date:  2015-10-16

8.  Molecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western Kenya.

Authors:  Clement Zeh; Seth C Inzaule; Pascale Ondoa; Lillian G Nafisa; Alex Kasembeli; Fredrick Otieno; Hilde Vandenhoudt; Pauli N Amornkul; Lisa A Mills; John N Nkengasong
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

9.  Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities.

Authors:  Micah Oyaro; John Wylie; Chien-Yu Chen; Raphael O Ondondo; Anna Kramvis
Journal:  South Afr J HIV Med       Date:  2018-03-27       Impact factor: 2.744

10.  Socio-demographic and sexual practices associated with HIV infection in Kenyan injection and non-injection drug users.

Authors:  Valentine Budambula; Charles Matoka; James Ouma; Aabid A Ahmed; Michael F Otieno; Tom Were
Journal:  BMC Public Health       Date:  2018-01-30       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.